



**TTK Healthcare
LIMITED**

TTKHC:SEC:GJ:025:23

February 07, 2023

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra East
Mumbai 400 051

SCRIP CODE: 507747

SCRIP CODE: TTKHLTCARE

Dear Sirs,

**Re : Disclosure under Regulation 30 - Unaudited Financial Results along with Limited
Review Report for the Third Quarter and Period ended 31st December, 2022**

We are forwarding herewith the Unaudited Financial Results along with the Limited Review Report from the Statutory Auditors of the Company, for the Third Quarter and Period ended 31st December, 2022, duly reviewed by the Audit Committee at their meeting held yesterday (i.e.) on 6th February, 2023 and approved by the Board of Directors of the Company at their Meeting held today.

The Board Meeting commenced at 12 noon concluded at 1.00 p.m.

Kindly take the above documents on record.

Thanking you

Yours faithfully
For TTK Healthcare Limited

(S KALYANARAMAN)
Wholetime Director & Secretary

Encl. : a/a



TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED 31ST DECEMBER, 2022

[Prepared in compliance with the Indian Accounting Standards (Ind AS)]

(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			For the period ended		For the Year ended
		(31/12/2022)	(30/09/2022)	(31/12/2021)	(31/12/2022)	(31/12/2021)	(31/03/2022)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I.	Revenue from Operations	18,256.08	16,979.18	15,872.47	54,497.29	44,056.97	59,923.99
II.	Other Income	1,179.34	1,106.28	445.62	3,271.85	1,112.28	1,633.06
III.	Total Income (I + II)	19,435.42	18,085.46	16,318.09	57,769.14	45,169.25	61,557.05
IV.	Expenses:						
	(a) Cost of materials consumed	4,754.08	4,596.36	3,850.26	13,680.50	9,952.77	14,346.23
	(b) Purchase of Stock-in-trade	4,284.97	3,868.00	4,202.73	12,539.72	10,418.24	15,040.39
	(c) Changes in inventories of Finished Goods, Work-in-progress and Stock-in-trade	(526.91)	(114.43)	(476.43)	(88.93)	(385.34)	(1,237.15)
	(d) Employee benefits expense	3,223.19	3,124.81	2,524.63	9,568.15	7,246.89	10,284.24
	(e) Finance Costs	78.02	79.61	143.87	428.54	226.86	323.75
	(f) Depreciation and Amortization Expense	320.90	332.08	316.25	972.73	946.60	1,258.36
	(g) Other Expenses	5,678.29	5,105.44	4,926.88	17,180.43	15,109.01	19,306.55
	Total Expenses (IV)	17,812.54	16,991.87	15,488.19	54,281.14	43,515.03	59,322.37
V.	Profit / (Loss) before Exceptional Items and Tax (III - IV)	1,622.88	1,093.59	829.90	3,488.00	1,654.22	2,234.68
VI.	Exceptional Items [Refer Note No.4 below]	-	-	-	-	249.05	249.05
VII.	Profit / (Loss) before Tax (V - VI)	1,622.88	1,093.59	829.90	3,488.00	1,903.27	2,483.73
VIII.	Tax Expense:						
	(1) Current Tax	459.95	333.00	243.09	1,071.03	565.24	743.67
	(2) Deferred Tax	(36.69)	(30.77)	(29.07)	(7.87)	(90.55)	(110.96)
IX.	Profit / (Loss) for the period from Continuing Operations (VII-VIII)	1,199.62	791.36	615.88	2,424.84	1,428.58	1,851.02
X.	Profit / (Loss) from Discontinued Operations [Refer Note No.3(a) below]	-	-	847.51	77,643.92	2,373.05	3,294.14
XI.	Tax Expense from Discontinued Operations [Refer Note No.3(b) below]	-	(199.95)	246.91	17,791.74	704.76	986.33
XII.	Profit / (Loss) from Discontinued Operations (after tax) (X - XI)	-	199.95	600.60	59,852.18	1,668.29	2,307.81
XIII.	Profit / (Loss) for the period (IX + XII)	1,199.62	991.31	1,216.48	62,277.02	3,096.87	4,158.83
XIV.	Other Comprehensive Income:						
	(A) (i) Items that will not be reclassified subsequently to profit or loss	(278.07)	235.04	180.00	(44.25)	485.90	213.31
	(ii) Income tax relating to items that will not be reclassified to profit or loss	31.81	(26.89)	(20.59)	5.06	(54.75)	(25.82)
	(B) (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV.	Total Comprehensive Income for the period (XIII + XIV) [Comprising Profit / (Loss) and Other Comprehensive Income for the period] including Human Pharma Operations - Discontinued	953.36	1,199.46	1,375.89	62,237.83	3,528.02	4,346.32
	Paid-up Equity Share Capital (Face Value Rs.10 per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
	Other Equity as per Balance Sheet (excluding Revaluation Reserve)	-	-	-	-	-	31,108.67
XVI.	Earnings per Equity Share (For Continuing Operations):						
	(1) Basic (in Rs.)	8.49	5.60	4.36	17.16	10.11	13.10
	(2) Diluted (in Rs.)	8.49	5.60	4.36	17.16	10.11	13.10

Sl. No.	Particulars	For the Quarter ended			For the period ended		For the Year ended
		(31/12/2022)	(30/09/2022)	(31/12/2021)	(31/12/2022)	(31/12/2021)	(31/03/2022)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
XVII.	Earnings per Equity Share (For Human Pharma Operations - Discontinued):						
(1)	Basic (in Rs.)	-	1.42	4.25	423.57	11.81	16.33
(2)	Diluted (in Rs.)	-	1.42	4.25	423.57	11.81	16.33
XVIII.	Earnings per Equity Share (For Continuing and Human Pharma Operations - Discontinued):						
(1)	Basic (in Rs.)	8.49	7.02	8.61	440.73	21.92	29.43
(2)	Diluted (in Rs.)	8.49	7.02	8.61	440.73	21.92	29.43

Notes:

- (1) The above financial results for the Third Quarter and Period ended 31st December, 2022 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee at its meeting held on 6th February, 2023 and approved by the Board of Directors of the Company at its meeting held on 7th February, 2023 at the Registered Office of the Company, also with the provision of Video Conferencing facility.
- (2) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (3) (a) Profit from Discontinued Operations:
- (i) Gain on Sale of Undertaking:
- During the First Quarter, the necessary formalities for transfer of the Human Pharma Division (Undertaking) of the Company were completed and the Division stood transferred as a going concern on slump sale basis for a consideration of Rs.80,500 lakhs (final consideration of Rs.80,281.54 lakhs after working capital and other customary adjustments) to M/s.BSV Pharma Private Ltd (BSV) with effect from 9th May, 2022.
- The consideration for the transfer was 74% cash (Rs. 59,442.51 lakhs) and 26% in the form of equity of the buying entity. The terms of transfer also provide for purchase of the aforesaid 26% Equity Shares held by the Company in BSV, by M/s Bharat Serums and Vaccines Limited or its Nominees, after they obtain necessary regulatory clearances, at the issue price.
- During the current quarter, the above shares have been transferred to M/s Bharat Serums and Vaccines Limited and the consideration of Rs.20,839.03 lakhs for the shares has been received by the Company.
- The gain on sale of this Undertaking amounts to Rs.76,429.45 lakhs (after providing for Rs.1,500.00 lakhs towards contingencies of which the Company has incurred expenses amounting to Rs.266.58 lakhs till 31st December, 2022).
- (ii) Profit from Human Pharma Operations:
- The total income of Human Pharma Division up to the date of sale (i.e.) 9th May, 2022 was Rs.2,240.57 lakhs (including reversal of provision made towards damaged / expired stock returns in the earlier years amounting to Rs.1,132.29 lakhs which was no longer required) and its total expenses were Rs.1,026.10 lakhs resulting in a net profit of Rs.1,214.47 lakhs.
- (b) Tax expense of Discontinued Operations:
- The tax expense on sale of Human Pharma Division is Rs.17,487.80 lakhs [(i.e.) Long Term Capital Gain tax expense on the above transfer amounting to Rs.17,770.01 lakhs net of Deferred Tax credit of Rs.282.21 lakhs].
- The tax expense on the profit for the nine month ended 31st December, 2022 from the operations of Human Pharma Division was Rs.303.94 lakhs, net of reversal of Rs.199.95 lakhs.
- (4) Exceptional Items relating to FY 2021-22: In September, 2021, the Company sold land admeasuring 4.595 acres held by it at Perungudi Village, Tirunelveli District, Tamil Nadu on which the Company had earned a profit of Rs.249.05 lakhs.
- (5) Implementation of the Code of Social Security 2020, which is likely to impact the contributions by the Company towards Provident Fund, Gratuity and other related areas has been deferred by the Government beyond 1st April, 2021. However, the Company based on the initial assessment made a provision for Rs.350 lakhs in the Fourth Quarter of FY 2020-21 and proposes to take further appropriate action after the Rules are made applicable.
- (6) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.
- (7) This Statement is also available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).

For TTK HEALTHCARE LIMITED



Place : Chennai
Date : Feburary 07, 2023

T T RAGHUNATHAN
Executive Chairman



TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086
 CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

**SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER AND PERIOD ENDED
 31ST DECEMBER, 2022**

(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			For the Period ended		For the Year ended
		(31/12/2022)	(30/09/2022)	(31/12/2021)	(31/12/2022)	(31/12/2021)	(31/03/2022)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Segment Revenue: (Sales and Other Operating Income)						
(a)	Animal Welfare Division	2,735.91	2,713.05	2,667.76	7,932.45	7,438.15	9,910.79
(b)	Consumer Products	5,740.61	5,660.00	5,509.16	18,985.92	16,679.69	21,743.70
(c)	Medical Devices	1,962.79	1,612.28	1,522.36	5,507.92	3,500.97	5,091.90
(d)	Protective Devices	5,059.48	4,268.47	3,671.93	13,850.10	9,439.52	13,326.15
(e)	Foods	2,751.84	2,714.88	2,491.53	8,192.65	6,980.78	9,803.44
(f)	Others	5.45	10.50	9.73	28.26	17.86	48.01
(g)	Human Pharma-Discontinued Operations	-	-	5,376.96	1,107.20	14,907.13	19,804.34
	Total	18,256.08	16,979.18	21,249.43	55,604.50	58,964.10	79,728.33
	Less : Inter Segment Revenue	-	-	-	-	-	-
	Net Sales / Income from Operations	18,256.08	16,979.18	21,249.43	55,604.50	58,964.10	79,728.33
2.	Segment Results: [Profit (+) / Loss (-) before tax and interest from each segment]						
(a)	Animal Welfare Division	203.78	172.57	284.95	461.66	823.41	928.71
(b)	Consumer Products	651.33	565.70	518.77	1,866.51	1,552.19	2,323.23
(c)	Medical Devices	227.67	239.35	187.64	767.47	247.33	319.68
(d)	Protective Devices	389.77	76.28	(40.90)	571.18	(511.70)	(536.22)
(e)	Foods	(130.88)	(146.51)	(30.49)	(413.75)	(199.83)	(244.69)
(f)	Others	4.85	8.05	6.02	20.09	13.90	33.00
(g)	Human Pharma-Discontinued Operations [Refer Note No.4 (a) below]	-	-	1,038.40	77,651.59	2,887.72	4,001.61
	Total	1,346.52	915.44	1,964.39	80,924.75	4,813.02	6,825.32
	Less : Finance Cost	78.01	79.61	148.60	436.20	266.55	396.24
	Less : Unallocable Expenses (Net of Unallocable Income)	(354.37)	(257.76)	138.38	(643.37)	270.15	651.21
	Total Profit (+) / Loss (-) before tax	1,622.88	1,093.59	1,677.41	81,131.92	4,276.32	5,777.87
		As on 31/12/2022	As on 30/09/2022	As on 31/12/2021	As on 31/12/2022	As on 31/12/2021	As on 31/03/2022
3.	Segment Assets:						
(a)	Animal Welfare Division	4,271.17	4,110.97	6,743.90	4,271.17	6,743.90	4,044.75
(b)	Consumer Products	3,379.75	3,716.25	2,966.88	3,379.75	2,966.88	4,017.12
(c)	Medical Devices	5,605.72	5,430.18	4,596.37	5,605.72	4,596.37	4,382.64
(d)	Protective Devices	11,551.94	9,697.63	9,459.50	11,551.94	9,459.50	8,449.60
(e)	Foods	8,357.56	8,688.59	9,519.77	8,357.56	9,519.77	9,610.29
(f)	Others	227.00	219.03	185.89	227.00	185.89	208.32
(g)	Human Pharma - Assets of Discontinued Business	-	-	-	-	-	2,428.66
	Total	33,393.14	31,862.65	33,472.31	33,393.14	33,472.31	33,141.38
	Unallocated [Refer Note No.4 (b) below]	86,750.13	91,925.68	27,768.35	86,750.13	27,768.35	28,327.64
	Total Assets	1,20,143.27	1,23,788.33	61,240.66	1,20,143.27	61,240.66	61,469.02
4.	Segment Liabilities:						
(a)	Animal Welfare Division	4,383.43	4,925.40	7,638.91	4,383.43	7,638.91	5,311.75
(b)	Consumer Products	5,958.69	6,041.62	6,926.12	5,958.69	6,926.12	6,419.38
(c)	Medical Devices	1,949.60	2,057.54	1,756.16	1,949.60	1,756.16	1,527.73
(d)	Protective Devices	4,980.93	3,719.57	3,783.18	4,980.93	3,783.18	3,389.08
(e)	Foods	1,709.34	1,627.22	1,497.11	1,709.34	1,497.11	1,556.44
(f)	Others	133.93	133.47	135.01	133.93	135.01	141.37
(g)	Human Pharma - Liabilities of Discontinued Business	-	-	-	-	-	2,148.66
	Total	19,115.92	18,504.82	21,736.49	19,115.92	21,736.49	20,494.41
	Unallocated	7,239.42	12,448.93	7,359.26	7,239.42	7,359.26	8,011.47
	Total Liabilities	26,355.34	30,953.75	29,095.75	26,355.34	29,095.75	28,505.88

Notes:

1. Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management.
2. Details of products included in each of the Segments are as below :
 - ❖ Animal Welfare (earlier included in Pharmaceuticals Segment) comprise products for Veterinary use.
 - ❖ Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home Range of Scrubbers, Air Freshners, etc.
 - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
 - ❖ Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products.
 - ❖ Foods comprise manufacturing and marketing of Food Products.
 - ❖ "Others" include Printing and Publishing of Maps and Atlases.
 - ❖ Human Pharma (earlier included in Pharmaceuticals Segment) comprise products for Human use
3. Segment Assets and Segment Liabilities shown under Animal Welfare Division as at 31st December, 2021 include that of Human Pharma Division also.
4. (a) Segment Results of Human Pharma Division include gain on sale of the Division amounting to Rs.76,429.45 lakhs.
(b) Unallocated Segment Assets include consideration on sale of Human Pharma Division received in the form of cash and equity.
5. The Segmentwise Revenue, Results, Assets and Liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
6. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED



T T RAGHUNATHAN
Executive Chairman

Place : Chennai
Date : February 07, 2023

**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086
 CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED 31ST DECEMBER, 2022

(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			For the Period ended		For the Year ended
		(31/12/2022)	(30/09/2022)	(31/12/2021)	(31/12/2022)	(31/12/2021)	(31/03/2022)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Total income from Operations	18,256.08	16,979.18	21,249.43	55,604.50	58,964.10	79,728.33
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	1,622.88	1,093.59	1,677.41	81,131.92	4,027.27	5,528.82
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items) [Refer Note No.6 below]	1,622.88	1,093.59	1,677.41	81,131.92	4,276.32	5,777.87
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items) [Refer Note No.6 below]	1,199.62	991.31	1,216.48	62,277.02	3,096.87	4,158.83
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]	953.36	1,199.46	1,375.89	62,237.83	3,528.02	4,346.32
6.	Equity Share Capital (Face Value of Rs.10/- per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
7.	Other Equity as per Balance Sheet of previous accounting year (excluding Revaluation Reserve)	-	-	-	-	-	31,108.67
8.	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)						
	(a) Basic (in Rs.)	8.49	7.02	8.61	440.73	21.92	29.43
	(b) Diluted (in Rs.)	8.49	7.02	8.61	440.73	21.92	29.43

Notes:

- The above is an extract of the detailed Statement of Unaudited Financial Results for the Third Quarter and Period ended 31st December, 2022, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The full financial results for the Third Quarter and Period ended 31st December, 2022 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).
- These financial results have been reviewed by the Audit Committee at its meeting held on 6th February, 2023 and approved by the Board of Directors of the Company at its meeting held on 7th February, 2023 at the Registered Office of the Company also with the provision of Video Conferencing facility.
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (a) Profit from Discontinued Operations:
 - Gain on Sale of Undertaking:
 During the First Quarter, the necessary formalities for transfer of the Human Pharma Division (Undertaking) of the Company were completed and the Division stood transferred as a going concern on slump sale basis for a consideration of Rs.80,500 lakhs (final consideration of Rs.80,281.54 lakhs after working capital and other customary adjustments) to M/s.BSV Pharma Private Ltd (BSV), with effect from 9th May, 2022.

 The consideration for the transfer was 74% cash (Rs. 59,442.51 lakhs) and 26% in the form of equity of the buying entity. The terms of transfer also provide for purchase of the aforesaid 26% Equity Shares held by the Company in BSV, by M/s Bharat Serums and Vaccines Limited or its Nominees, after they obtain necessary regulatory clearances, at the issue price.

 During the current quarter, the above shares have been transferred to M/s Bharat Serums and Vaccines Limited and the consideration of Rs.20,839.03 lakhs for the shares has been received by the Company.

 The gain on sale of this Undertaking amounts to Rs.76,429.45 lakhs (after providing for Rs.1,500.00 lakhs towards contingencies of which the Company has incurred expenses amounting to Rs.266.58 lakhs till 31st December, 2022).
 - Profit from Human Pharma Operations:
 The total income of Human Pharma Division up to the date of sale (i.e.) 9th May, 2022 was Rs.2,240.57 lakhs (including reversal of provision made towards damaged / expired stock returns in the earlier years amounting to Rs.1,132.29 lakhs which was no longer required) and its total expenses were Rs.1,026.10 lakhs resulting in a net profit of Rs.1,214.47 lakhs.
- (b) Tax expense of Discontinued Operations:
 The tax expense on sale of Human Pharma Division is Rs.17,487.80 lakhs [(i.e.) Long Term Capital Gain tax expense on the above transfer amounting to Rs.17,770.01 lakhs net of Deferred Tax credit of Rs.282.21 lakhs].

 The tax expense on the profit for the nine month ended 31st December, 2022 from the operations of Human Pharma Division was Rs.303.94 lakhs, net of reversal of Rs.199.95 lakhs.
- Exceptional Items relating to FY 2021-22: In September, 2021, the Company sold land admeasuring 4.595 acres held by it at Perungudi Village, Tirunelveli District, Tamil Nadu on which the Company had earned a profit of Rs.249.05 lakhs.
- Implementation of the Code of Social Security 2020, which is likely to impact the contributions by the Company towards Provident Fund, Gratuity and other related areas has been deferred by the Government beyond 1st April, 2021. However, the Company based on the initial assessment made a provision for Rs.350 lakhs in the Fourth Quarter of FY 2020-21 and proposes to take further appropriate action after the Rules are made applicable.
- The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED

T T RAGHUNATHAN
 Executive Chairman

Place : Chennai
 Date : February 07, 2023

PKF SRIDHAR & SANTHANAM LLP

Chartered Accountants

Independent Auditor's Review Report on review of Interim financial results

To the Board of Directors of TTK Healthcare Limited

We have reviewed the accompanying Statement of Unaudited financial results ("the Statement") of TTK Healthcare Limited ("the Company") for the quarter and period ended 31st December 2022. The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing obligations) which has been initialed by us for identification purposes.

Management's Responsibility

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

Auditor's Responsibility

Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **PKF Sridhar & Santhanam LLP**

Chartered Accountants

Firm's Registration No. 003990S/S200018

S Rajeshwari

Partner

Membership No. 024105



Place: Chennai

Date: 07th February, 2023

UDIN No: 23024105BGYMFA1640

Tel +91 44 28112985 to 88 • Fax +91 44 28112989 • Email sands@pkfindia.in • www.pkfindia.in

PKF SRIDHAR & SANTHANAM LLP • KRD Gee Gee Crystal • No.91-92 7th Floor • Dr.Radhakrishnan Salai • Mylapore • Chennai 600004

REGISTRATION NO. WITH ICAI IS 003990S/S200018